查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1534371

非何杰金氏淋巴瘤治疗市场：全球规模、份额、趋势分析、机会、预测，2019-2030

Non-Hodgkin Lymphoma Therapeutics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019-2030, Segmented By Therapy Type; By Drug Class; By Route of Administration; By End User; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2030年全球非何杰金氏淋巴瘤治疗市场规模将达205亿美元

由于非何杰金氏淋巴瘤盛行率的上升、老年人口的扩大以及生物技术进步的迅速采用，全球非何杰金氏淋巴瘤治疗市场正在迅速扩大。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年全球非何杰金氏淋巴瘤治疗市场规模以金额为准123 亿美元。 BlueWeave预测，2024年至2030年的预测期内，全球非何杰金氏淋巴瘤治疗市场规模将以8.90%的复合年增长率成长，到2023年达到205亿美元。全球非何杰金氏淋巴瘤治疗市场是由发病率上升、诊断技术进步以及包括标靶治疗和免疫疗法在内的创新疗法的市场发展所推动的。医疗保健支出的增加、早期诊断意识的提高以及政府的支持措施也促进了市场的成长。此外，全球人口老化、免疫力缺乏疾病日益普及以及製药公司对研发的大量投资也进一步推动了市场扩张。总之，这些因素增加了非何杰金氏淋巴瘤患者治疗选择的可用性和有效性。

机会－新药联合治疗的开发

创新药物联合治疗正在彻底改变非何杰金氏淋巴瘤(NHL) 治疗并推动市场扩张。这些联合治疗通常将标靶治疗与传统化疗或免疫疗法结合起来，提高疗效，同时最大限度地减少副作用。随着个人化治疗方法的进步，製药公司正在大力投资研发，以确定协同效应药物对并优化治疗方法。此外，精准医疗和生物标记主导治疗的出现进一步强化了这一趋势，为不同的非何杰金氏淋巴瘤亚型提供了量身定制的解决方案。因此，市场正在加速成长，有望改善结果和改善患者照护。

地缘政治紧张局势加剧对全球非何杰金氏淋巴瘤治疗市场的影响

地缘政治紧张局势的加剧对全球非何杰金氏淋巴瘤治疗市场产生重大影响。俄罗斯-乌克兰战争等衝突造成的供应链中断可能会减缓药品的生产和分配。贸易限制和製裁阻碍了基本原料和药品的取得。例如，COVID-19 大流行加剧了这些问题，并凸显了全球供应链的脆弱性。此外，国防支出的增加可能会转移医疗保健资金并影响研发投资。地缘政治不稳定造成的不确定性也会导致市场状况波动，进而影响投资者信心和新治疗方法的资金筹措。因此，维持稳定的地缘政治环境对于确保淋巴瘤治疗的持续进展和可用性至关重要。

全球非何杰金氏淋巴瘤治疗市场

按细分市场分類的覆盖范围

非何杰金氏淋巴瘤治疗的全球市场 – 按给药途径划分

根据给药途径，全球非何杰金氏淋巴瘤治疗市场分为口服、静脉注射、皮下注射和鞘内注射。在全球非何杰金氏淋巴瘤治疗市场中，静脉注射注射占最大份额。这一优点归因于静脉注射疗法在非何杰金氏淋巴瘤治疗方案中的广泛使用。静脉注射可将药物快速输送到血流中，从而实现高效且有效的治疗。新生物製药和静脉注射单株抗体的引入也推动了这一领域的成长，这些药物已成为淋巴瘤治疗的标准。这一趋势预计将持续下去，该领域的市场主导地位将进一步加强。

竞争格局

全球非何杰金氏淋巴瘤治疗市场竞争激烈。市场主要企业包括阿斯利康公司、拜耳公司、罗氏公司、葛兰素史克公司、Seagen Inc.、武田製药有限公司、杨森製药公司、礼来公司、Spectrum Pharmaceuticals Inc.、百时美施贵宝公司和艾伯维。这些公司正在增加对研发活动、併购、联盟、授权合约的投资，并发布新产品和服务，以进一步加强其在全球非何杰金氏淋巴瘤治疗市场的地位。

该报告的详细分析提供了有关全球非何杰金氏淋巴瘤治疗市场的成长潜力、未来趋势和统计数据的资讯。它还涵盖了推动市场总规模预测的因素。该报告致力于提供全球非何杰金氏淋巴瘤治疗市场的最新技术趋势和产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章全球非何杰金氏淋巴瘤治疗市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 非何杰金氏淋巴瘤发生率上升
      • 越来越多地采用标靶治疗和免疫疗法
      • 人口老化加剧
    • 抑制因素
      • 治疗费用上涨
      • 有限退费政策
      • 严格的监管核准流程
    • 机会
      • 新药联合治疗的开发
      • 潜力开拓的新兴市场
      • 个人化医疗日益受到关注
    • 任务
      • 復发/难治性病例的抗药性
      • 与治疗相关的副作用
      • 维持医疗保健系统的永续性
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球非何杰金氏淋巴瘤治疗市场：行销策略

第五章全球非何杰金氏淋巴瘤治疗市场：价格分析

第六章全球非何杰金氏淋巴瘤治疗市场：区域分析

  • 全球非何杰金氏淋巴瘤治疗市场，区域分析，2023 年
  • 2024-2030年全球非何杰金氏淋巴瘤治疗市场吸引力分析

第七章 全球非何杰金氏淋巴瘤治疗市场概述

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
      • 化疗
      • 免疫疗法
      • 标靶治疗
      • 放射治疗
      • 干细胞移植
    • 按药品类别
      • 单株抗体
      • 蛋白酪氨酸激酶抑制剂
      • 蛋白酶体抑制剂
      • 组蛋白去乙酰化酶抑制剂
      • 抗代谢物
    • 依给药途径
      • 口服
      • 静脉
      • 皮下注射
      • 椎管内的
    • 按最终用户
      • 医院
      • 专科诊所
      • 门诊手术中心
      • 家庭护理设置
    • 按国家/地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲（中东/非洲）

第八章北美非何杰金氏淋巴瘤治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
    • 按药品类别
    • 依给药途径
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第九章欧洲非何杰金氏淋巴瘤治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
    • 按药物类别
    • 依给药途径
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第十章亚太非何非何杰金氏淋巴瘤治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
    • 按药品类别
    • 依给药途径
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第十一章拉丁美洲非何杰金氏淋巴瘤治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
    • 按药品类别
    • 依给药途径
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第十二章中东与非洲非何杰金氏淋巴瘤治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按治疗类型
    • 按药物类别
    • 依给药途径
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 中东和非洲其他地区

第十三章竞争格局

  • 主要企业及其驱动器类型列表
  • 2023年全球非何杰金氏淋巴瘤治疗市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 重大策略发展（合併、收购、联盟等）

第十四章全球非何杰金氏淋巴瘤治疗市场：进出口

第十五章地缘政治紧张局势加剧对全球非何杰金氏淋巴瘤治疗市场的影响

第十六章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络方式、策略展望、SWOT分析）

  • AstraZeneca Plc
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Seagen Inc.
  • Takeda Pharmaceutical Company Limited
  • Janssen Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc.
  • Bristol Myers Squibb Co.
  • AbbVie
  • 其他主要企业

第十七章 主要战略建议

第十八章调查方法

简介目录
Product Code: BWC24515

Global Non-Hodgkin Lymphoma Therapeutics Market Size to Touch Value of USD 20.5 Billion by 2030

Global Non-Hodgkin Lymphoma Therapeutics Market is expanding rapidly due to the rising prevalence of the disease, expanding geriatric population, and rapid adoption of advancements in biotechnology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Non-Hodgkin Lymphoma Therapeutics Market size by value at USD 12.3 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Non-Hodgkin Lymphoma Therapeutics Market size to expand at a CAGR of 8.90% reaching a value of USD 20.5 billion in 2023. Global Non-Hodgkin Lymphoma Therapeutics Market is driven by rising incidence rates of the disease, advancements in diagnostic techniques, and the development of innovative treatments, including targeted therapies and immunotherapies. Increased healthcare expenditure, growing awareness about early diagnosis, and supportive government initiatives also contribute to market growth. Additionally, an aging global population, a higher prevalence of immunodeficiency disorders, and significant investments in research and development by pharmaceutical companies further propel the market expansion. These factors collectively enhance the availability and efficacy of therapeutic options for patients with non-Hodgkin lymphoma.

Opportunity - Development of novel drug combinations

Innovative drug combinations are revolutionizing Non-Hodgkin Lymphoma (NHL) treatment, propelling market expansion. These combinations, often integrating targeted therapies with traditional chemotherapy or immunotherapy, enhance efficacy while minimizing adverse effects. With an increasingly personalized approach to treatment, pharmaceutical companies are investing heavily in research and development to identify synergistic drug pairs and optimize treatment regimens. Moreover, the emergence of precision medicine and biomarker-driven therapies further augments the trend, offering tailored solutions for different NHL subtypes. Consequently, the market witnesses accelerated growth, driven by the promise of improved outcomes and enhanced patient care.

Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market

Escalating geopolitical tensions significantly impact Global Non-Hodgkin Lymphoma Therapeutics Market. Disruptions in the supply chain due to conflicts, such as the Russia-Ukraine war, can delay drug production and distribution. Trade restrictions and sanctions hinder the availability of essential raw materials and pharmaceuticals. For instance, the COVID-19 pandemic exacerbated these issues, highlighting the vulnerability of global supply chains. Additionally, increased defense spending can divert funds from healthcare, affecting research and development investments. The uncertainty caused by geopolitical instability may also lead to fluctuating market conditions, affecting investor confidence and funding for new therapies. Thus, maintaining a stable geopolitical environment is crucial for ensuring continuous advancements and availability in lymphoma treatments.

Global Non-Hodgkin Lymphoma Therapeutics Market

Segmental Coverage

Global Non-Hodgkin Lymphoma Therapeutics Market - By Route of Administration

Based on route of administration, Global Non-Hodgkin Lymphoma Therapeutics Market is divided into Oral, Intravenous, Subcutaneous, and Intrathecal segments. The intravenous segment holds the largest share in Global Non-Hodgkin Lymphoma Therapeutics Market. The dominance is due to the widespread use of intravenous therapies in the treatment protocols for non-Hodgkin lymphoma. Intravenous administration allows for rapid delivery of drugs into the bloodstream, ensuring efficient and effective treatment. The segment's growth is also driven by the introduction of new intravenous biologics and monoclonal antibodies, which have become standard in lymphoma care. The trend is expected to continue, reinforcing the segment's leading position in the market.

Competitive Landscape

Global Non-Hodgkin Lymphoma Therapeutics Market is fiercely competitive. Major companies in the market include AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Seagen Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals Inc., Eli Lilly and Company, Spectrum Pharmaceuticals Inc., Bristol Myers Squibb Co., and AbbVie. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Non-Hodgkin Lymphoma Therapeutics Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Non-Hodgkin Lymphoma Therapeutics Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technology trends in Global Non-Hodgkin Lymphoma Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Therapy Type Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Non-Hodgkin Lymphoma Therapeutics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising Prevalence of Non-Hodgkin Lymphoma
      • 3.2.1.2. Increasing Adoption of Targeted Therapies and Immunotherapy
      • 3.2.1.3. Growing Geriatric Population
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of Treatments
      • 3.2.2.2. Limited Reimbursement Policies
      • 3.2.2.3. Stringent Regulatory Approval Process
    • 3.2.3. Opportunities
      • 3.2.3.1. Development of Novel Drug Combinations
      • 3.2.3.2. Emerging Markets with Untapped Potential
      • 3.2.3.3. Rising Focus on Personalized Medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Drug Resistance in Relapsed/Refractory Cases
      • 3.2.4.2. Side Effects Associated with Therapies
      • 3.2.4.3. Maintaining Sustainability in Healthcare Systems
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Non-Hodgkin Lymphoma Therapeutics Market: Marketing Strategies

5. Global Non-Hodgkin Lymphoma Therapeutics Market: Pricing Analysis

6. Global Non-Hodgkin Lymphoma Therapeutics Market: Geography Analysis

  • 6.1. Global Non-Hodgkin Lymphoma Therapeutics Market, Geographical Analysis, 2023
  • 6.2. Global Non-Hodgkin Lymphoma Therapeutics Market Attractiveness Analysis, 2024-2030

7. Global Non-Hodgkin Lymphoma Therapeutics Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
      • 7.2.1.1. Chemotherapy
      • 7.2.1.2. Immunotherapy
      • 7.2.1.3. Targeted Therapy
      • 7.2.1.4. Radiation Therapy
      • 7.2.1.5. Stem Cell Transplantation
    • 7.2.2. By Drug Class
      • 7.2.2.1. Monoclonal Antibodies
      • 7.2.2.2. Tyrosine Kinase Inhibitors
      • 7.2.2.3. Proteasome Inhibitors
      • 7.2.2.4. Histone Deacetylase Inhibitors
      • 7.2.2.5. Antimetabolites
    • 7.2.3. By Route of Administration
      • 7.2.3.1. Oral
      • 7.2.3.2. Intravenous
      • 7.2.3.3. Subcutaneous
      • 7.2.3.4. Intrathecal
    • 7.2.4. By End User
      • 7.2.4.1. Hospitals
      • 7.2.4.2. Specialty Clinics
      • 7.2.4.3. Ambulatory Surgical Centers
      • 7.2.4.4. Homecare Settings
    • 7.2.5. By Country
      • 7.2.5.1. North America
      • 7.2.5.2. Europe
      • 7.2.5.3. Asia Pacific (APAC)
      • 7.2.5.4. Latin America (LATAM)
      • 7.2.5.5. Middle East and Africa (MEA)

8. North America Non-Hodgkin Lymphoma Therapeutics Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
      • 8.2.5.1. United States
      • 8.2.5.1.1. By Therapy Type
      • 8.2.5.1.2. By Drug Class
      • 8.2.5.1.3. By Route of Administration
      • 8.2.5.1.4. By End User
      • 8.2.5.2. Canada
      • 8.2.5.2.1. By Therapy Type
      • 8.2.5.2.2. By Drug Class
      • 8.2.5.2.3. By Route of Administration
      • 8.2.5.2.4. By End User

9. Europe Non-Hodgkin Lymphoma Therapeutics Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
      • 9.2.5.1. Germany
      • 9.2.5.1.1. By Therapy Type
      • 9.2.5.1.2. By Drug Class
      • 9.2.5.1.3. By Route of Administration
      • 9.2.5.1.4. By End User
      • 9.2.5.2. United Kingdom
      • 9.2.5.2.1. By Therapy Type
      • 9.2.5.2.2. By Drug Class
      • 9.2.5.2.3. By Route of Administration
      • 9.2.5.2.4. By End User
      • 9.2.5.3. Italy
      • 9.2.5.3.1. By Therapy Type
      • 9.2.5.3.2. By Drug Class
      • 9.2.5.3.3. By Route of Administration
      • 9.2.5.3.4. By End User
      • 9.2.5.4. France
      • 9.2.5.4.1. By Therapy Type
      • 9.2.5.4.2. By Drug Class
      • 9.2.5.4.3. By Route of Administration
      • 9.2.5.4.4. By End User
      • 9.2.5.5. Spain
      • 9.2.5.5.1. By Therapy Type
      • 9.2.5.5.2. By Drug Class
      • 9.2.5.5.3. By Route of Administration
      • 9.2.5.5.4. By End User
      • 9.2.5.6. Belgium
      • 9.2.5.6.1. By Therapy Type
      • 9.2.5.6.2. By Drug Class
      • 9.2.5.6.3. By Route of Administration
      • 9.2.5.6.4. By End User
      • 9.2.5.7. Russia
      • 9.2.5.7.1. By Therapy Type
      • 9.2.5.7.2. By Drug Class
      • 9.2.5.7.3. By Route of Administration
      • 9.2.5.7.4. By End User
      • 9.2.5.8. The Netherlands
      • 9.2.5.8.1. By Therapy Type
      • 9.2.5.8.2. By Drug Class
      • 9.2.5.8.3. By Route of Administration
      • 9.2.5.8.4. By End User
      • 9.2.5.9. Rest of Europe
      • 9.2.5.9.1. By Therapy Type
      • 9.2.5.9.2. By Drug Class
      • 9.2.5.9.3. By Route of Administration
      • 9.2.5.9.4. By End User

10. Asia Pacific Non-Hodgkin Lymphoma Therapeutics Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
      • 10.2.5.1. China
      • 10.2.5.1.1. By Therapy Type
      • 10.2.5.1.2. By Drug Class
      • 10.2.5.1.3. By Route of Administration
      • 10.2.5.1.4. By End User
      • 10.2.5.2. India
      • 10.2.5.2.1. By Therapy Type
      • 10.2.5.2.2. By Drug Class
      • 10.2.5.2.3. By Route of Administration
      • 10.2.5.2.4. By End User
      • 10.2.5.3. Japan
      • 10.2.5.3.1. By Therapy Type
      • 10.2.5.3.2. By Drug Class
      • 10.2.5.3.3. By Route of Administration
      • 10.2.5.3.4. By End User
      • 10.2.5.4. South Korea
      • 10.2.5.4.1. By Therapy Type
      • 10.2.5.4.2. By Drug Class
      • 10.2.5.4.3. By Route of Administration
      • 10.2.5.4.4. By End User
      • 10.2.5.5. Australia & New Zealand
      • 10.2.5.5.1. By Therapy Type
      • 10.2.5.5.2. By Drug Class
      • 10.2.5.5.3. By Route of Administration
      • 10.2.5.5.4. By End User
      • 10.2.5.6. Indonesia
      • 10.2.5.6.1. By Therapy Type
      • 10.2.5.6.2. By Drug Class
      • 10.2.5.6.3. By Route of Administration
      • 10.2.5.6.4. By End User
      • 10.2.5.7. Malaysia
      • 10.2.5.7.1. By Therapy Type
      • 10.2.5.7.2. By Drug Class
      • 10.2.5.7.3. By Route of Administration
      • 10.2.5.7.4. By End User
      • 10.2.5.8. Singapore
      • 10.2.5.8.1. By Therapy Type
      • 10.2.5.8.2. By Drug Class
      • 10.2.5.8.3. By Route of Administration
      • 10.2.5.8.4. By End User
      • 10.2.5.9. Vietnam
      • 10.2.5.9.1. By Therapy Type
      • 10.2.5.9.2. By Drug Class
      • 10.2.5.9.3. By Route of Administration
      • 10.2.5.9.4. By End User
      • 10.2.5.10. Rest of APAC
      • 10.2.5.10.1. By Therapy Type
      • 10.2.5.10.2. By Drug Class
      • 10.2.5.10.3. By Route of Administration
      • 10.2.5.10.4. By End User

11. Latin America Non-Hodgkin Lymphoma Therapeutics Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Therapy Type
    • 11.2.2. By Drug Class
    • 11.2.3. By Route of Administration
    • 11.2.4. By End User
    • 11.2.5. By Country
      • 11.2.5.1. Brazil
      • 11.2.5.1.1. By Therapy Type
      • 11.2.5.1.2. By Drug Class
      • 11.2.5.1.3. By Route of Administration
      • 11.2.5.1.4. By End User
      • 11.2.5.2. Mexico
      • 11.2.5.2.1. By Therapy Type
      • 11.2.5.2.2. By Drug Class
      • 11.2.5.2.3. By Route of Administration
      • 11.2.5.2.4. By End User
      • 11.2.5.3. Argentina
      • 11.2.5.3.1. By Therapy Type
      • 11.2.5.3.2. By Drug Class
      • 11.2.5.3.3. By Route of Administration
      • 11.2.5.3.4. By End User
      • 11.2.5.4. Peru
      • 11.2.5.4.1. By Therapy Type
      • 11.2.5.4.2. By Drug Class
      • 11.2.5.4.3. By Route of Administration
      • 11.2.5.4.4. By End User
      • 11.2.5.5. Rest of LATAM
      • 11.2.5.5.1. By Therapy Type
      • 11.2.5.5.2. By Drug Class
      • 11.2.5.5.3. By Route of Administration
      • 11.2.5.5.4. By End User

12. Middle East & Africa Non-Hodgkin Lymphoma Therapeutics Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Therapy Type
    • 12.2.2. By Drug Class
    • 12.2.3. By Route of Administration
    • 12.2.4. By End User
    • 12.2.5. By Country
      • 12.2.5.1. Saudi Arabia
      • 12.2.5.1.1. By Therapy Type
      • 12.2.5.1.2. By Drug Class
      • 12.2.5.1.3. By Route of Administration
      • 12.2.5.1.4. By End User
      • 12.2.5.2. UAE
      • 12.2.5.2.1. By Therapy Type
      • 12.2.5.2.2. By Drug Class
      • 12.2.5.2.3. By Route of Administration
      • 12.2.5.2.4. By End User
      • 12.2.5.3. Qatar
      • 12.2.5.3.1. By Therapy Type
      • 12.2.5.3.2. By Drug Class
      • 12.2.5.3.3. By Route of Administration
      • 12.2.5.3.4. By End User
      • 12.2.5.4. Kuwait
      • 12.2.5.4.1. By Therapy Type
      • 12.2.5.4.2. By Drug Class
      • 12.2.5.4.3. By Route of Administration
      • 12.2.5.4.4. By End User
      • 12.2.5.5. South Africa
      • 12.2.5.5.1. By Therapy Type
      • 12.2.5.5.2. By Drug Class
      • 12.2.5.5.3. By Route of Administration
      • 12.2.5.5.4. By End User
      • 12.2.5.6. Nigeria
      • 12.2.5.6.1. By Therapy Type
      • 12.2.5.6.2. By Drug Class
      • 12.2.5.6.3. By Route of Administration
      • 12.2.5.6.4. By End User
      • 12.2.5.7. Algeria
      • 12.2.5.7.1. By Therapy Type
      • 12.2.5.7.2. By Drug Class
      • 12.2.5.7.3. By Route of Administration
      • 12.2.5.7.4. By End User
      • 12.2.5.8. Rest of MEA
      • 12.2.5.8.1. By Therapy Type
      • 12.2.5.8.2. By Drug Class
      • 12.2.5.8.3. By Route of Administration
      • 12.2.5.8.4. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Drive Types
  • 13.2. Global Non-Hodgkin Lymphoma Therapeutics Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Global Non-Hodgkin Lymphoma Therapeutics Market: Import & Export

15. Impact of Escalating Geopolitical Tensions on Global Non-Hodgkin Lymphoma Therapeutics Market

16. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 16.1. AstraZeneca Plc
  • 16.2. Bayer AG
  • 16.3. F. Hoffmann-La Roche Ltd
  • 16.4. GlaxoSmithKline Plc
  • 16.5. Seagen Inc.
  • 16.6. Takeda Pharmaceutical Company Limited
  • 16.7. Janssen Pharmaceuticals Inc.
  • 16.8. Eli Lilly and Company
  • 16.9. Spectrum Pharmaceuticals Inc.
  • 16.10. Bristol Myers Squibb Co.
  • 16.11. AbbVie
  • 16.12. Other Prominent Players

17. Key Strategic Recommendations

18. Research Methodology

  • 18.1. Qualitative Research
    • 18.1.1. Primary & Secondary Research
  • 18.2. Quantitative Research
  • 18.3. Market Breakdown & Data Triangulation
    • 18.3.1. Secondary Research
    • 18.3.2. Primary Research
  • 18.4. Breakdown of Primary Research Respondents, By Region
  • 18.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable